FibroBiologics (FBLG) Cash & Equivalents (2022 - 2026)

FibroBiologics has reported Cash & Equivalents for 5 years, with the latest figure at $3.5 million in Q2 2026.

• Cash & Equivalents for Q2 2026 came in at $3.5 million, down 60.26% year-over-year; the trailing twelve-month figure through Jun 2026 was $3.5 million (down 60.26% YoY), and the FY2025 annual result was $4.9 million, down 65.0% from the prior year.
• Cash & Equivalents climbed to $3.5 million in Q2 2026, from $1.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $14.0 million in Q4 2024 and troughed at $1.5 million in Q1 2026.
• A 5-year average of $6.6 million and a median of $6.9 million in 2024 frame the typical range for Cash & Equivalents.
• The widest annual swing landed in 2023, when Cash & Equivalents soared 304.37%; it then tumbled 82.69% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $2.3 million in 2022, then surged by 304.37% to $9.2 million in 2023, then jumped by 52.79% to $14.0 million in 2024, then sank by 65.0% to $4.9 million in 2025, then fell by 28.27% to $3.5 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $3.5 million in Q2 2026, $1.5 million in Q1 2026, and $4.9 million in Q4 2025.